Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Sequencing one Topo-1 payload ADC directly after another yields diminished patient benefit, even when alternating surface targets like TROP-2 and HER2. Dr. Tolaney notes that while some patients still respond, resistance appears predominantly driven by the chemotherapy payload rather than target mutations.

Related Insights

When sequencing antibody-drug conjugates, switching payloads reduces cross-resistance risk, and emerging evidence shows sequential activity even when targeting the same receptor with distinct payloads. However, clinicians express major concern that sequencing one topoisomerase-1 payload ADC after another could attenuate the second drug's activity, making the initial payload choice critical across gynecologic malignancies.

When sequencing antibody-drug conjugates, clinical experience suggests that resistance to the chemotherapy payload is a primary driver of failure. Therefore, oncologists tend to avoid using another ADC with the same payload consecutively, preferring to switch both target and payload if possible.

Retrospective data shows that using one Antibody-Drug Conjugate (ADC) after another, particularly those with the same class of payload like TOP1 inhibitors, results in a low response rate of 10-20%. This creates a significant unmet need and a major clinical challenge for patients who progress on a first-line ADC.

Most approved ADCs for breast cancer utilize a topoisomerase-1 inhibitor payload. This common mechanism raises a critical question about cross-resistance, making the sequencing of these agents a significant clinical challenge without clear data to guide decisions on their subsequent use after progression.

A significant clinical challenge is the sequencing of antibody-drug conjugates (ADCs). Retrospective data from large databases indicates that using a second TROP2-targeted ADC after a first one provides very limited efficacy, highlighting an urgent need for prospective trials to define optimal sequencing strategies and overcome resistance.

Most new antibody-drug conjugates (ADCs) for ovarian cancer use the same topoisomerase-1 (Topo1) inhibitor payload. This similarity will likely prevent their sequential use due to cross-resistance, forcing clinicians into a "one-shot" scenario where they must choose the single best Topo1-based ADC upfront for a patient.

With 18 of 19 ADCs in development for SCLC using a topoisomerase-1 inhibitor payload, there's a significant risk that patients may not respond to a second ADC after progressing on a first. This highlights a critical need to develop ADCs with alternative payloads to provide more therapeutic options and overcome resistance.

As more antibody-drug conjugates (ADCs) become available, a key concern is resistance to the cytotoxic payload. If a tumor develops resistance to a topoisomerase-1 inhibitor from one ADC, it may not respond to other ADCs using the same payload, regardless of their different antibody targets, complicating future treatment sequencing.

When patients progress on an antibody-drug conjugate (ADC), the resistance is frequently due to the tumor becoming resistant to the chemotherapy payload (e.g., a topoisomerase inhibitor). This is more common than the tumor losing the surface target, which critically impacts the sequencing of subsequent ADCs.

Nearly all promising antibody-drug conjugates (ADCs) in late-stage development for small cell lung cancer utilize a topoisomerase-1 (Topo-1) inhibitor payload. This overlap raises a critical clinical question: if a patient develops resistance to one ADC, will they respond to another? This creates a significant challenge for treatment sequencing and patient selection.